Miranda Lankas

Miranda Lankas, Assistant Editor for CURE®, started at MJH Life sciences in August 2022. She completed an undergraduate and Master of Arts degree in literature at Temple University. Miranda’s passions include embroidery, color guard, and picking up new languages. Email her in English, French, or Japanese at mlankas@mjhlifesciences.com.

Young Age, Triple-Negative Disease May Increase Brain Metastases Risk in Inflammatory Breast Cancer

October 18, 2022

These results, which showed that a patient with inflammatory breast cancer may have an increased risk for brain metastases if certain factors are present, may alert patients and doctors to consider routine brain scans while they undergo treatment for their disease.

Many Survivors of GISTs, a Rare Cancer, May Experience Cancer-Related Cognitive Impairments After Treatment

October 05, 2022

Nearly two thirds of patients with GISTs — a rare type of cancer that often begins in the digestive system — indicated that their overall quality of life after treatment had been affected by cancer-related cognitive impairments, also referred to as “chemo brain,” according to analysis of survey data.

Adding a Certain Immunotherapy Drug to Chemotherapy May Benefit Patients With Thymoma, a Type of Rare Cancer

September 26, 2022

The addition of Bavencio to an Inlyta regimen may help stabilize disease in some patients with thymic carcinoma, but one expert stressed that checkpoint inhibitors are “problematic” for patients diagnosed with thymoma, a type of rare cancer.

Men With Breast Cancer May Respond Less to Neoadjuvant Chemotherapy Versus Women

September 15, 2022

Although rates of pathologic complete response to neoadjuvant — also known as presurgical — chemotherapy were lower in men than women with breast cancer, this may highlight an area of further research of treating this cancer in men.

Addition of Empliciti to Combination Regimen Continues to Show Benefit in Previously Treated Multiple Myeloma

August 29, 2022

Long-term follow-up shows that treatment with Empliciti plus pomalidomide and dexamethasone continues to significantly increase survival rates in patients with relapsed or refractory multiple myeloma, a persistent cancer affecting white blood cells that may be resistant to treatment.

Few Patients With Breast Cancer Are Educated on Treatments' Affects on Sexual Health

August 08, 2022

Although very few patients are informed about the effects that breast cancer treatments may have on their sexual health, many patients expressed wanting that information throughout all stages of their treatment, according to study findings.